File Download
Supplementary
-
Citations:
- Appears in Collections:
Article: Novel therapeutic agents for T-cell lymphomas
Title | Novel therapeutic agents for T-cell lymphomas |
---|---|
Authors | |
Issue Date | 2013 |
Publisher | Solariz, Inc. The Journal's web site is located at http://www.discoverymedicine.com |
Citation | Discovery Medicine, 2013, v. 16 n. 86, p. 27-35 How to Cite? |
Abstract | T-cell lymphomas are a heterogeneous group of T-cell malignancies arising from post-thymic mature T-cells. Together they account for 10-15% of all non-Hodgkin's lymphoma. Because of the different underlying pathology, different T-cell lymphoma subtypes may require different treatment approaches. In general, the treatment results of T-cell lymphomas, using conventional anthracycline-based combination chemotherapy, are disappointing. Though autologous or allogeneic stem cell transplantation may offer a cure to some of the patients, a substantial proportion of patients are not eligible for transplantation because of the chemo-refractoriness or short remission duration of the lymphomas. Novel therapies may open up the potential path for better disease control. We review several classes of novel treatment for T-cell lymphomas including monoclonal antibodies, epigenetic modifiers, newer generation of cytotoxics, and specific targeting agents that may improve treatment outcome |
Persistent Identifier | http://hdl.handle.net/10722/203090 |
ISSN | 2023 Impact Factor: 2.0 2020 SCImago Journal Rankings: 0.913 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, TSY | en_US |
dc.contributor.author | Kwong, YL | en_US |
dc.contributor.author | Tse, EWC | en_US |
dc.date.accessioned | 2014-09-19T11:29:49Z | - |
dc.date.available | 2014-09-19T11:29:49Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | Discovery Medicine, 2013, v. 16 n. 86, p. 27-35 | en_US |
dc.identifier.issn | 1539-6509 | - |
dc.identifier.uri | http://hdl.handle.net/10722/203090 | - |
dc.description.abstract | T-cell lymphomas are a heterogeneous group of T-cell malignancies arising from post-thymic mature T-cells. Together they account for 10-15% of all non-Hodgkin's lymphoma. Because of the different underlying pathology, different T-cell lymphoma subtypes may require different treatment approaches. In general, the treatment results of T-cell lymphomas, using conventional anthracycline-based combination chemotherapy, are disappointing. Though autologous or allogeneic stem cell transplantation may offer a cure to some of the patients, a substantial proportion of patients are not eligible for transplantation because of the chemo-refractoriness or short remission duration of the lymphomas. Novel therapies may open up the potential path for better disease control. We review several classes of novel treatment for T-cell lymphomas including monoclonal antibodies, epigenetic modifiers, newer generation of cytotoxics, and specific targeting agents that may improve treatment outcome | en_US |
dc.language | eng | en_US |
dc.publisher | Solariz, Inc. The Journal's web site is located at http://www.discoverymedicine.com | - |
dc.relation.ispartof | Discovery Medicine | en_US |
dc.title | Novel therapeutic agents for T-cell lymphomas | en_US |
dc.type | Article | en_US |
dc.identifier.email | Kwong, YL: ylkwong@hku.hk | en_US |
dc.identifier.email | Tse, EWC: ewctse@hku.hk | en_US |
dc.identifier.authority | Kwong, YL=rp00358 | en_US |
dc.identifier.authority | Tse, EWC=rp00471 | en_US |
dc.description.nature | link_to_OA_fulltext | - |
dc.identifier.hkuros | 237441 | en_US |
dc.identifier.volume | 16 | en_US |
dc.identifier.issue | 86 | en_US |
dc.identifier.spage | 27 | en_US |
dc.identifier.epage | 35 | en_US |
dc.publisher.place | United States | - |
dc.identifier.issnl | 1539-6509 | - |